1.88
price up icon2.17%   0.04
after-market 시간 외 거래: 1.87 -0.010 -0.53%
loading
전일 마감가:
$1.84
열려 있는:
$1.84
하루 거래량:
26,361
Relative Volume:
0.12
시가총액:
$73.83M
수익:
-
순이익/손실:
$-41.36M
주가수익비율:
-1.1463
EPS:
-1.64
순현금흐름:
$-42.09M
1주 성능:
+1.08%
1개월 성능:
-0.53%
6개월 성능:
-7.85%
1년 성능:
-36.05%
1일 변동 폭
Value
$1.8107
$1.985
1주일 범위
Value
$1.75
$2.00
52주 변동 폭
Value
$0.8981
$3.4154

Armata Pharmaceuticals Inc Stock (ARMP) Company Profile

Name
명칭
Armata Pharmaceuticals Inc
Name
전화
310-655-2928
Name
주소
4503 Glencoe Avenue, Marina del Rey, CA
Name
직원
33
Name
트위터
Name
다음 수익 날짜
2025-03-19
Name
최신 SEC 제출 서류
Name
ARMP's Discussions on Twitter

ARMP을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ARMP
Armata Pharmaceuticals Inc
1.88 73.83M 0 -41.36M -42.09M -1.64
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.27 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
522.27 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.00 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
568.06 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
266.80 28.51B 3.81B -644.79M -669.77M -6.24

Armata Pharmaceuticals Inc Stock (ARMP) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2019-06-19 개시 Ladenburg Thalmann Buy

Armata Pharmaceuticals Inc 주식(ARMP)의 최신 뉴스

pulisher
Jun 13, 2025

Armata Pharmaceuticals Elects Board Members at Annual Meeting - TipRanks

Jun 13, 2025
pulisher
Jun 11, 2025

Chronic Pseudomonas aeruginosa Pulmonary Infections Pipeline - openPR.com

Jun 11, 2025
pulisher
Jun 03, 2025

Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection - Seeking Alpha

Jun 03, 2025
pulisher
Jun 02, 2025

Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Declines By 44.0% - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

10 Best Healthcare Stocks to Invest In (June 2025) - Securities.io

Jun 01, 2025
pulisher
May 25, 2025

ARMP Soars 72% in a Month Following Infectious Disease Study Success - MSN

May 25, 2025
pulisher
May 23, 2025

8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - GlobeNewswire Inc.

May 23, 2025
pulisher
May 22, 2025

Biotech Alert: Searches spiking for these stocks today - TipRanks

May 22, 2025
pulisher
May 22, 2025

Armata Pharmaceuticals (ARMP) Experiences Massive Surge in Inter - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Armata Pharmaceuticals Q4 EPS Reduced by HC Wainwright - Defense World

May 22, 2025
pulisher
May 20, 2025

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Price Target Raised to $9.00 at HC Wainwright - Defense World

May 20, 2025
pulisher
May 19, 2025

Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia | ARMP Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Armata Pharmaceuticals (ARMP) Receives Boosted Price Target from - GuruFocus

May 19, 2025
pulisher
May 19, 2025

HC Wainwright Adjusts Armata Pharmaceuticals Price Target to $9 From $7, Maintains Buy Rating - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

Armata Pharmaceuticals (ARMP) Price Target Boosted Following Cli - GuruFocus

May 19, 2025
pulisher
May 19, 2025

ARMP: Positive Results from Armata Pharmaceuticals' AP-SA02 Tria - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Armata reports data from Phase 1b/2a diSArm trial - TipRanks

May 19, 2025
pulisher
May 19, 2025

Armata Pharmaceuticals Announces Positive Topline Data from the - GuruFocus

May 19, 2025
pulisher
May 19, 2025

ARMP: Positive Results from Armata Pharmaceuticals' AP-SA02 Trial | ARMP Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Armata Pharmaceuticals Reports Positive Phase 1b/2a Trial Results - TipRanks

May 19, 2025
pulisher
May 19, 2025

Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia - PR Newswire

May 19, 2025
pulisher
May 15, 2025

Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates - MSN

May 15, 2025
pulisher
May 14, 2025

Armata Pharmaceuticals Inc (ARMP) Q1 Earnings: EPS Loss of $0.18 - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update | ARMP Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update - Financial Times

May 14, 2025
pulisher
May 08, 2025

New Strong Sell Stocks for May 8th - The Globe and Mail

May 08, 2025
pulisher
May 05, 2025

Armata Pharmaceuticals (ARMP) to Release Earnings on Tuesday - Defense World

May 05, 2025
pulisher
May 02, 2025

Armata Pharmaceuticals secures additional DoD funding - Investing.com

May 02, 2025
pulisher
May 01, 2025

Armata Pharmaceuticals (ARMP) Secures Additional $4.65M for Clin - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Armata Pharmaceuticals Receives $4.65 Million of Additional Non- - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 | ARMP Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Armata Pharmaceuticals secures additional DoD funding By Investing.com - Investing.com Nigeria

May 01, 2025
pulisher
May 01, 2025

Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 - Yahoo Finance

May 01, 2025
pulisher
Apr 28, 2025

New Strong Sell Stocks for April 28th - The Globe and Mail

Apr 28, 2025
pulisher
Apr 24, 2025

New Strong Sell Stocks for April 24th - TradingView

Apr 24, 2025
pulisher
Apr 01, 2025

Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Expands By 28.3% - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

Bacteriophage Therapy Market Future Business Opportunities - openPR

Mar 31, 2025
pulisher
Mar 24, 2025

HC Wainwright Comments on Armata Pharmaceuticals Q1 Earnings - Defense World

Mar 24, 2025
pulisher
Mar 21, 2025

Armata Pharmaceuticals Inc (ARMP) Q4 2024 Earnings: EPS of $0.07 - GuruFocus

Mar 21, 2025
pulisher
Mar 21, 2025

Armata Pharmaceuticals reports Q4 EPS (23c) vs (55c) last year - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

Armata Pharmaceuticals Inc. (ARMP) reports earnings - Quartz

Mar 21, 2025
pulisher
Mar 20, 2025

Armata Pharmaceuticals Announces Fourth Quarter And Full-Year 2024 Results And Provides Corporate Update - MarketScreener

Mar 20, 2025
pulisher
Mar 20, 2025

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update - PR Newswire

Mar 20, 2025
pulisher
Mar 18, 2025

Armata Pharmaceuticals (ARMP) Projected to Post Quarterly Earnings on Thursday - The AM Reporter

Mar 18, 2025
pulisher
Mar 12, 2025

Armata Pharmaceuticals secures $10 million credit By Investing.com - Investing.com Australia

Mar 12, 2025
pulisher
Mar 12, 2025

Armata Pharmaceuticals secures $10 million credit - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

Armata Pharmaceuticals Secures $10M Loan for Clinical Trials - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva - Eastern Progress

Mar 12, 2025

Armata Pharmaceuticals Inc (ARMP) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.74
price up icon 0.29%
$36.14
price up icon 2.09%
$20.92
price up icon 2.60%
$105.90
price up icon 0.46%
$105.09
price up icon 2.02%
biotechnology ONC
$266.80
price up icon 3.61%
자본화:     |  볼륨(24시간):